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Abstract 
Parkinson's Disease (PD) is a neurological disorder that results in patients 
suffering from bradykinesia, tremor, rigidity and postural instability. The 
neuropathology of PD involves the loss of dopaminergic neurons in the substantia 
nigra (SN) and massive dopamine depletion in the striatum The molecular mechanism 
underlying this dopaminergic neuron cell death, however, is still unclear. There are 
several hypotheses established to explain the etiology of PD. The formation of nitric 
oxide (NO) has recently been proposed to play a role in mediating the nigral cell death. 
However, there is so far no direct evidence that NO is produced in the eNS in PD 
patients although iNOS positive cells were shown to be present in the SN of PD 
postmortem brains. 
l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) has been widely used as 
a model for studying the etiology of PD. Since astrocytes are the main site of MPTP 
conversion to its toxic metabolite N-methyl-4-phenylpyridinium (MPP+), and have a 
high content of antioxidants to protect the cells from free radical-induced damage, they 
were used in the present study where NO production under MPTP treatment was 
investigated. Astrocytes were shown to produce large amounts of NO in some other 
neurodegenerative disorders upon cytokine stimulation, therefore it would be of 
interest to examine whether MPTP can also stimulate the production of NO in 
astrocytes and thus be involved in the pathogenesis of PD. 
Nitric oxide synthase (NOS) expression and the time course of NO production 
is also be examined. Astrocytes were cultured from ventral mesencephalon, striatum 
and cortex and were treated with 500flM MPTP from 0 - 72 h. In order to measure the 
level of NO produced, extracellular nitrite and intracellular cGMP levels were 
IV 
measured by the Griess reaction and radioimmunoassay, respectively. NOS inhibitors 
were used to confirm the source of NO measured. Immunocytochemical staining for 
the p65 subunit of NFKB was used to confirm the induction of iNOS in the production 
of the NO observed. Since NO can react with 02"- to form the highly reactive ONOO-, 
superoxide dismutase (SOD) activities in these cells were also analysed. 
The present study shows that there is an increase in nitrite and cGMP levels in 
astrocytes after MPTP treatment. However, there was a differential response in NO 
production with mesencephalic astrocytes producing the highest amount of NO 
followed by striatal astrocytes, and cortical astrocytes showed minllnal change. NOS 
inhibitors, including L-NAME and dexamethasone, were employed to confirm which 
isoform of NOS contributed to the increase in NO. It was shown that L-NAME and 
dexamethasone can completely block NO production suggesting that iNOS is involved 
in this process. This was further confirmed by NFKB positively stained nuclei in all 3 
types of astrocytes confirming the involvement of iNOS in this process. Striatal 
astrocytes showed an early (4 h) transcriptional activation of iNOS whilst cortical and 
mesencephalic astrocytes showed iNOS transcription at 8 h post-treatment. 
Cortical astrocytes were found to have a higher basal SOD level than the other 
two regions. There was a 50% decrease in SOD activity in mesencephalic astrocytes 
24 h after MPTP treatment. Striatal astrocytes, however, showed a transient 
upregulation of SOD at 8 h post-treatment with minllnal change observed for the 
cortical astrocytes ~ The present results showed that there was a regional difference in 
terms of NO production as well as antioxidant level among the different types of 
astrocytes. Mesencephalic astrocytes, with a high level of NO production, presence of 
02"- as well as low SOD activity will favour the fonnation of peroxynitrite and are 
v 
therefore more susceptible to oxidative-induced injury. As a result, this may render 
their neighbouring dopaminergic neuronal cell bodies more conducive to NO-mediated 
injuries. 
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CHAPTER ONE: INTRODUCTION 
1.1 Parkinson's Disease 
1.1.1 Epidemiology 
Parkinson's disease (PD) was first mentioned by James Parkinson in his book 
"An Essay on the Shaking Palsy" (Pearce, 1989). In that book, he described a 
collection of associated clinical features of paralytic disorders and tremors: 
"involuntary tremulous motion, with lessened muscular power, in parts not in action 
and even when supported, with a propensity to bend trunk forward, and to pass from a 
walking to a running pace, the senses and intellects being uninjured." (Pearce, 1989). 
His nineteenth century colleagues then named this constellation of symptoms and signs 
his "disease". 
There are various epidemiologic studies demonstrating the prevalence ratio of 
PD among the different populations in the world (Fig. 1) (Roman et al., 1989). The 
occurrence of PD in different countries seems to have different frequencies. It was 
reported that White and Black Americans had a much higher incidence when compared 
to Asians (Tanner, 1989). It was estimated that between 1 to 2 persons in 1000 of the 
Caucasian population has PD (Marttila and Rinne, 1987). There seemed to be no 
difference in the rate of occurrence between sexes (Rajput et al., 1984; Schoenberg et 
al., 1985; Roman et al., 1995) although in one study, a male predominance was shown 
(Kessler, 1978). Environmental factors were also proposed to play a role in the 
etiology of PD. In a study of early onset PD patients « 41 years) in Saskatchewan, 
Canada, Rajput et al. (1987) found that these cases occurred in rural areas more often 
than expected and that these patients used well water. They hypothesized that some 
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agents in the water may be responsible for PD. Similar results were reported from a 
study carried out in China. (fanner, 1989). 
Other than environmental influence, the association of dietary factors with PD 
was also investigated (Golbe et al., 1988). Seventeen food items were selected for 
examination and none of them were found to be associated with the presence of PD. 
However, an unexpected association of nuts, salad oil and plums with the absence of 
PD was discovered. The reason may be due to the high level of the antioxidant, 
vitamin E, in these food items (Golbe et al., 1988). 
1.1.2 Clinical symptoms 
The major clinical symptoms observed in PD patients include resting tremor, an 
unique increase in muscle rigidity, postural instability and bradykinesia (Nutt et al. 
1992). 
Tremor is a recognizable initial symptom of PD. It is of a resting type with a 
frequency of 4-6 Hz and diminishes during action. Resting tremor usually starts from 
one side of the body and affects the extremities first. It may spread to the other side of 
the body over months or it may remain asymmetric. The tremor can also be stimulated 
by stress and fatigue. 
Rigidity in PD is characterized by a waxing resistance in passive movement. It 
can be most easily detected at the patient's wrist and elbow joint. The joint cannot be 
moved smoothly, resulting in a cogwheel phenomenon during testing. 
Two types of postural disturbance can be identified: static and kinetic. The 
static type may be manifested as scoliosis, a stooped posture and dystonic hand or foot 
with flexed metacarpophalangeal joints, extended proximal interphalangeal joints and 
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flexed distal iriterphalangeal joints. The kinetic type indicates the loss of balance during 
the execution of daily tasks, such as the patient will have difficulty in attempting to rise 
from the chair or adapting to an unexpected disturbance of postural equilibrium. 
Bradykinesia, means slowness of movement, is manifested in the patient's 
difficulty in initiating, arresting and slowness in execution of movement. The sequential 
actions may also be interrupted by an intermittent immobility or "freezing", thus 
impairing the smooth execution of daily tasks. This is most apparent when the patient 
undresses or searches his/her pocket or purse. An extreme form of bradykinesia is 
akinesia, referring to the complete absence of movement. This may last for several 
seconds to hours and is most evident when the patient starts the gait. 
Apart from the motor deficit, it is now recognized that other systems are also 
affected. Autonomic dysfunction can account for the diaphoresis and constipation 
observed in the patients. The disease may be accompanied by depression, dementia and 
bradyphrenia. PD presents a complex syndrome with rich and variable expressions in 
different patients which often result in diagnostic difficulty and delayed treatment 
(Jankovic, 1992). 
1.1.3 Neuropathology 
The neuropathologies of PD involve first, a characteristic pattern of 
degeneration of dopaminergic neurons in the pars compacta of the substantia nigra 
(SN) (Gibb et al., 1991). Second, there is a depletion (70% to 80%) of striatal 
dopamine (DA) with an uneven distribution where the depletion in the putamen DA 
exceeds that of the caudate (Kish, 1988). Although Lewy bodies (eosinophilic 
intracytoplasmic inclusions) were found in some of the remaining neurons in the 
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substantia nigra of PD patients (Jellinger, 1989), and are often regarded as the 
hallmark of PD, they are also common in several neurological disorders like 
Alzheimer's disease and are present in some normal aging brains (Gibb, 1987). Glia 
scar formation was also found in the SN region and was suggested to be the result of a 
secondary reaction to the nerve cell loss (Fomo et al., 1992). 
1.2 Proposed mechanisms of Neuronal Cell Death in PD 
The selective and progressive destruction of the nigrostriatal dopaminergic 
neurons in PD patients is still unknown. Many studies have suggested that the disease 
process may be dependent on factors such as free radicals generated in the CNS, 
dysfunction of mitochondria, excitotoxicity, genetic inheritance or even aging. 
1.2.1 Oxidative Stress 
Among the numerous mechanisms that can cause PD, oxidative stress has been 
the one that has received most attention in the past decade (Fahn and Co hen, 1992). 
Oxidative stress is defined as a toxic condition in which the cellular 
oxidation/reduction (redox) balance is shifted toward oxidation. This may occur as a 
consequence of accumulation of reactive oxygen species (ROS) like superoxide (02"-), 
hydrogen peroxide (H20 2) and hydroxyl radical (OH). Though direct evidence of the 
involvement of these reactive molecules in the patho genesis of PD is still lacking, the 
unique biochemical changes in PD brains suggest that oxidative stress may play an 
important role. Postmortem studies on parkinsonian brains showed that there is an 
increase in the activity of superoXide dismutase (SOD) (Saggu et al., 1989; Hirsch, 
1992), decrease in reduced glutathione (GSH) content (Perry and Yong, 1986; 
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Riederer et al., 1989; Di Monte et al., 1992a; Sofic et al., 1992), reduced activity of 
glutathione peroxidase (GSH-Px) and catalase (CAT) (Ambani et al., 1975; Kish et al., 
1985) in the SN. This implies that GSH-Px may not be able to cope with the potential 
increased formation of H20 2 , leading to further production of OH'. Decreased 
iron(II)/iron(III) ratio (Sofic et al., 1988), increased nigral iron content (Dexter et al., 
198Qa; Riederer et al., 1989), decreased brain ferritin level (Dexter et al., 1991) and 
lipid peroxidation (Dexter et al., 1989b) have also been shown in the SN of PD. 
Moreover, when an iron salt was injected intranigrally into rats, it produced a 
'parkinsonian-type' behaviour (Ben-Shachar and Youdim, 1991), consistent with the 
proposal that iron-driven oxidative reactions play a role in PD. Although there is a 
substantial body of indirect evidence implicating oxidative stress as a cause of PD, it is 
uncertain whether oxidative stress represents a primary causative event or just a 
secondary response to other noxious processes. 
1.2.2 Mitochondrial Dysfunction 
The mitochondrion is traditionally described as the "power house" of the cell. 
It is the organelle where several enzyme systems of metabolic pathways reside (Hatefi, 
1985). They are responsible for providing the cell with energy in the fonn of adenosine 
triphosphate (ATP). The enzyme complex which endows the mitochondria with a 
highly efficient supply of A TP is the respiratory chain, situated in the mitochondrial 
inner membrane and comprising four protein complexes, assigned as complex I 
(NADH-ubiquinone reductase), 11 (succinate-ubiquinone reductase), III 
(ubiquinone-cytochrome c reductase) and IV (cytochrome c oxidase). Working 
together with ATP synthase, the chain carries out the process called oxidative 
5 
phosphorylation with oxidation of NADH and FADH2, reduction of molecular oxygen 
(02) and formation of ATP (Fig. 2) (Pedersen, 1994). Since ATP is required for most 
of the cellular reactions, any means of interference with this process will affect normal 
cellular function and may finally cause cell death. 
Previous studies have shown that impaired mitochondrial function is a feature 
of pp (Schapira et al., 1992, 1994). The most consistent finding was decreased 
complex I activity in parkinsonian SN (Schapira et al., 1990a, b; Hattori et al., 1991; 
Mann et al., 1992; Janetzky et al., 1994). It was reported that no defect in 
mitochondrial function can be detected in other brain regions studied (Mizuno et al., 
1990; Mann et al., 1992; Cooper et al., 1995). 
It is still far from clear how mitochondrial dysfunctions arise and how these can 
contribute to neuronal cell death in PD. Since the respiratory chain is a major 
intracellular source of 02"- under aerobic condition and the inhibition of complex I has 
been shown to increase the generation of 02"- (Takeshige and Minakami, 1979; 
Hasegawa et al., 1990; Ramsay and Singer, 1992), this increase of 02"- may render the 
dopaminergic neurons in SN more susceptible to oxidative stress-induced cell death. 
Both in vivo and in vitro studies had shown that complex I and IV of the 
mitochondrial respiratory chain are more vulnerable to free radical damage (Hillered 
and Emster, 1983; Zhang et al., 1990; Benzi et al., 1991), leading to severe ATP 
depletion and cellular metabolic failure. Whether neuronal cell death is due to A TP 
depletion and/or free radicals insult remains unclear. 
1.2.3 Excitotoxicity 
Glutamate is one of the major excitatory amino acids in the eNS (Watkins and 
Evans, 1981; Fonnum, 1984). It can modulate the response of certain excitatory 
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Fig. 2 Mechanism of mitochondrial ATP synthesis. The 
respiratory chain of mammalian mitochondria is 
grouped into four polypeptide complexes. These 
include complex I (NADH-ubiquinone reductase), 
complex IT (Succinate-ubiquinone reductase), 
complex III (l:lbiquino-cytochrome c reductase) and 
complex IV. (cytochrome c oxidase). Complex I, III 
and IV act as oxidation-reduction-driven proton 
pumps. It then generates an electrochemical gradient 
of protons which consists of a membrane potential 
and a pH gradient. The electrochemical gradient 
across the membrane provides the driving force for 
phosphorylation of ADP to ATP by ATP synthase. 
This figure is used by the courtesy of Bolanos. J.P. from 1. Neurochem. 68 (1995) 
synapses to achieve synaptic plasticity which is thought to be crucial to normal brain 
functions such as memory and learning (Van Harreveld, 1974; Freed, 1981) On the 
other hand, over exposure to glutamate will destroy neurons via a process termed 
"excitotoxicity" (Olney et al., 1971). 
It is now recognized that glutamate 'ionotropic' receptors namely, 
N-l1X{thyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
(AMP A) and kainate receptors are largely responsible for mediating the excitotoxic 
effect of glutamate (Sacaan and Schoepp, 1992). These glutamate receptors are 
ligand-gated ion channels. When glutamate binds to the receptor, the ion channel 
opens and permits influx of Na+ or Ca2+ ions (MacDermott et al., 1986). The increased 
Ca2+ influx was suggested to play a pivotal role in glutamate excitotoxicity (Rothman, 
1992). In addition, Ca2+ can also bind to calmodulin and activate nitric oxide synthase 
and generate nitric oxide (Greenfield, 1993), resulting in lipid peroxidation (Choi, 
1988). A recent study showed that free radicals can inhibit a high affinity transport 
system in astrocytes that is responsible for the removal of extracellular glutamate 
(Volterra et al., 1994). This will · result in neurons entering an excitotoxic, 
self-amplifying cycle with subsequent neuronal cell death. Increased Ca2+ influx may 
also result in the non-specific activation of many enzymes including proteases, 
phospholipases, endonucleases, protein kinase C and xanthine oxidase, leading to 
aberrant control of signaling pathways and decreased integrity of the cytoskeleton 
(Nicotera and Orrenius, 1992). 
The observation of a mitochondrial complex I deficiency in PD brains 
suggested that there may exist an. impairment in the repolarization of the cells which 
will eventually diminish the Mg2+ block of the NMDA receptor-associated channels 
and render the receptors more easily activated by glutamate. One study found that 
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different glutamate receptor agonists produced parkinsonian symptoms when applied 
to different regions of the rat basal ganglia (Klockgether and Turski, 1993). NMD A 
and AMP A receptor antagonists, however, had antiparkinsonian effects (Greenamyre 
and O'Brien, 1991; Klockgether et al., 1991). Interestingly, there was a relatively 
selective loss of NMDA receptors as compared to receptors for other 
neurotransmitters in PD patients (Greenamyre et al., 1992). This may suggest that 
neurons expressing the NMDA receptor may be particularly vulnerable in this disease. 
Although there is insufficient evidence to implicate excitotoxicity as a causal 
factor of PD, glutamate undoubtedly plays a role in mediating or exacerbating the toxic 
effects of oxidative stress and energy impairment. 
1.2.4 Genetic Factors 
Earlier twin studies employed to evaluate the genetic component of PD 
showed a low concordance for PD in monozygotic as well as dizygotic twins, and the 
prevalence of PD in twins were comparable to that of the general population (Ward et 
al., 1983 and Marttila et al., 1988a). It was concluded that genetic factors did not play 
an essential role in the etiology of PD. However, 10hnson and co-workers (1990) 
reappraised the previous data of the twin studies based on clinical and statistical 
grounds. They revealed that the monozygotic twin concordance rate in fact 
significantly differed from that of the dizygotic twin concordance rate, suggesting a 
genetic component did exist for PD. They proposed the low concordance rate of the 
twins to PD observed earlier might be due to the short duration over which the 
observations were made. 
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Recently, a gene for a familial type of PD had been mapped to chromosome 
4q21 - q23 in a large Italian family (Polymeropoulos et al. 1996). Later, the mutated 
gene was found to code for a presynaptic protein called a-synuclein (Polymeropoulos 
et al., 1997). Patients from this study developed all the symptoms and pathological 
markers typical of idiopathic PD, and they also responded to levodopa therapy. The 
observations from this familial PD study suggested that there may also exist a genetic 
factor which may contribute to the cause of idiopathic PD. However, the role played 
by this mutated a-synuclein in the pathogenesis of idiopathic PD needs further 
confrrmation. 
1.2.5 Aging 
Most people develop PD between the age of 50 and 79. The occurrence rate 
is low below 50 but increases with age (Roman et al, 1995). Therefore, aging itself 
appears to be a key factor which contributes to the development of PD. In normal 
aging brains, it was shown that there is also a loss of dopaminergic cells in the zona 
compacta of the substantia nigra with advancing age (McGeer et al., 1977; Mann and 
Yates, 1983; Thiessen et al., 1990). In addition to the loss of these dopaminergic cells 
in the substantia nigra, there is a parallel loss of dopamine in the striatum The rate of 
striatal dopamine decline is approximately 5 to 8% per decade throughout life 
(Carlsson and Winblad, 1976). This decline may reflect a failure or at least an 
inadequate mechanism in which to protect the neurons from long-term damage due to 
free radical formation during aging. This hypothesis was supported by Felten and his 
colleagues (1992) who showed that 3-month-old C57BL/6 mice could recover from 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesion but not 12-month-old 
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mice. This may imply that the protective mechanism in the old mice may be less 
effective than young one. Moreover, the toxicity ofMPTP is greater in older mice than 
in younger mice (Saitoh et al., 1987), further suggesting the aging effect may also be a 
contributing factor to PO . 
. 
1.3 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a PO 
model 
1.3.1 Discovery of MPTP 
Oavis et al. (1979) reported the first case of parkinsonism occUrring after the 
intravenous self-administration of l-methyl-4-phenyl-4-propionooxypiperidine 
(MPPP), a meperidine analogue which is an illicit narcotic analgesic. The patients 
developed severe symptoms of parkinsonism and post-mortem brains of these patients 
also showed prominent pathological changes in nigrostriatal dopaminergic neurons 
similar to that of idiopathic PO. In 1982, a group of young drug addicts in northern 
California developed severe symptoms of parkinsonism after the injection of MPPP 
which was sold as "synthetic heroin". Finally, it was realized that during synthesis the 
byproduct MPTP, was contaminated MPPP and this synthetic chemical, MPTP, was 
later identified as the drug that induced permanent parkinsonism found in these addicts 
(Langston et al., 1983; Ballard et al., 1985). 
1.3.2 The mechanism of MPTP toxicity 
Subsequent to the discovery of MPTP in causing PO, MPTP was shown to be 
capable of leading to the selective destruction of nigrostriatal dopaminergic (OA) 
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neurons as well as resulting in marked dopamine depletion in the striatum in humans 
(Langston et al., 1983), monkeys (Burns et al., 1983) and mice (Heikkila et al., 1985). 
As a result, MPTP has been used as a tool to' study the mechanisms that underlie the 
degeneration of dopaminergic neurons and has been widely used as a PO model in the 
past decade. 
> MPTP requires a two-step process of metabolic activation in order to cause 
tissue damage. Frrst, MPTP IS converted to the 
l-methyl-4-phenyl-2,3-dihydropyridinium (MPD P+) intermediate, and then MPD P+ is 
further oxidized to fonn its toxic metabolite l-methyl-4-phenylpyridinium ion (MPP+) 
(Fig. 3). The conversion of MPTP to MPDP+ is catalyzed by an , enzyme called 
monoamine oxidase-B (MAO-B) (Chiba et al., 1984). However, to date there is no 
enzymatic activity or catalytic factors that have been identified are responsible for the 
subsequent formation of MPP+. It was later proposed that a nonenzymatic mechanism 
might be responsible for the formation of MPP+ because the rate of conversion from 
MPDP+ to MPP+ was quite similar in the presence or absence of cells (WU et al., 
1992). Further studies showed that astrocytes were the major site for the bioactivation 
ofMPTP via a MAO-B dependent pathway (Ransom et al. 1987; Schinelli et al., 1988; 
Brooks et al. 1989; Marini et al. 1989,; Di Monte et al., 1991). Although serotonergic 
neurons also contain MAO-B (Levitt et al. 1982; Westlund et al. 1985), contribution 
of these neuronal cell to MPP+ formation is unlikely to be significant because lesions of 
these neurons did not attenuate MPTP neurotoxicity (Me1amed et al. 1986; Brooks et 
al. 1989). This further suggested that astrocytes but not serotonergic neurons are the 






Fig. 3 Metabolism of I-methyl-4-phenyl-l,2,3,6-tetrahydropyridine 
(MPJP) to I-methyl-4-phenyl-pyridinium (MPP+). The 
oxidation of :MPTP to I-methyl-4-phenyl-2,3-
dihydropyridinium (MPDP+) and the subsequent conversion of 
this production to MPP+ is mediated by the action of 
monoamine oxidase-B (MAO-B). 
This figure is used by the courtesy of Kopin, I.J. from Advance in Neurology, vol 45: (1986) 
Parkinson's Disease 
MPDP+ and MPP+ formed in astrocytes might be able to diffuse out through 
the astrocyte cell membrane to the extracellular compartment (Di Monte et al., 1992b). 
The toxic metabolite MPP+ is then taken up actively into the nigrostriatal neurones via 
the dopamine transporter (Javitch and Synder, 1984). It had been shown that the 
dopamine uptake blocker mazindol could block MPP+ uptake, thus preventing the 
degel\erating effect of MPTP on nigrostriatal dopamine neurons (Javitch et al., 1985). 
After entering the cell, MPP+ was actively accumulated by mitochondria (Ramsay and 
Singer, 1986). The uptake process seemed to be driven the electrochemical potential 
of the mitochondrial membrane since the addition of valinomycin and potassium, which 
act as uncoup lers, abolished the accumulation of MPP+ (Ramsay et al., 1986). 
Subsequent accumulation of intracellular MPP+ inhibited complex I of the electron 
transport chain in mitochondria (Vyas et al. 1986) and led to the decline of ATP 
formation (Mizuno et al. 1987). The actions of MPP+ on mitochondrial respiratory 
function were strikingly similar to those found in PD (Kopin, 1987; Hollinden et al., 
1988; Ramsay et al., 1989). Thus, it had been suggested that environmental protoxins 
(Pinsky and Bose, 1988) or endogenous neurotoxic metabolites of dopamine like 
tetrahydro-~-carbolines and tetrahydroisoquinolines (Suzuki et al., 1988, 1990a, b; 
Sayre et al., 1991), with inhibitory ,actions on mitochondrial respiratory function 
similar to those of MPP+, might be the cause of the neurodegeneration in PD. 
However, studies showed that after the injection of 
2-methyl-1,2,3,4-tetrahydroisoquinoline and 2-methyl-l ,2,3,4-tetrahydro-~-carboline 
in mice and marmosets, there was a lack of dopaminergic nigrostriatal neurotoxicity 
... (Perry et al., 1987) or that the · toxicity was not so potent as that observed in 
MPTP-treated animals (Naoi et al., 1994). These results suggested that environmental 
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protoxins or endogenous neurotoxic DA metabolites may not be the prime candidates 
in the cause of PD. 
1.4 Reactive Oxygen Species (ROS) and Antioxidants in the eNS 
1.4.1 Superoxide (02"-) and Superoxide Oismutases (SOD) 
Superoxide radical (02-) is mainly produced in biological systems through 
one-electron reduction of O2• It is generated in vivo from the activity of electron 
transport chains in mitochondria and endoplasmic reticulum When the electrons pass 
through these chains, some of them leak directly from intermediate electron carriers 
onto O2 molecules. Since O2 accepts one electron each time, O2- is produced. Oi- can 
readily pass through membranes via an anion channel (Fridovich, 1978). However, 
mitochondria normally contain high levels of protective enzymes known as 
antioxidants to help remove toxic species; in the case of O2-, this protective enzyme is 
SOD (Jesberger and Richardson, 1991)~ 
O2- is metabolized by the metalloenzymes, SOD, to form hydrogen peroxide 
(H20 2) and molecular oxygen (Mc Cord . and Fridovich, 1969). 
SOD 
There are two distinct SODs in eukaryotic cells. The manganese-containing 
SOD (Mn-SOD) is localized almost exclusively in the matrix of the mitochondria. The 
copper- and zinc-containing SOD. (CuZn-SOD) is found mainly in the cytoplasm 
(Fridovich, 1978). There is also a small amount of extracellular SOD existing in the 
extracellular matrix. 
13 
Investigations into the role of SOD in the development of PD showed that 
mice pretreated with diethyl dithiocarbamate, an inhibitor of SOD, had enhanced 
MPTP-induced toxicity (Corsini et al. 1985). This might imply that 02"- may play a role 
in the toxic effect of MPTP. Furthermore, Przedborski et al. (1992) showed that, in 
transgenic mice, increased SOD activity could prevent neuronal degeneration and 
doprupine loss after MPTP treatment. These studies affirmed the protective role of 
SOD against MPTP-induced neurotoxicity. Further evidence that some of the 
deleterious effects of MPTP may be mediated by O2'- was provided by Poirier and 
Barbeau (1985), where 02"- was found to increase significantly during the in vitro 
biotransformation of MPTP. This suggested that O2'- may play a significant role in the 
etiology of PD. 
Further studies using L-deprenyl, a specific inhibitor of MAO-B, proved 
effective in preventing MPTP toxicity toward dopaminergic neurons. This might be 
achieved by the induction of CuZn-SOD and Mn-SOD expression using L-deprenyl at 
a low concentration, which is insufficient to inhibit MAO-B. (Carrillo et al., 1991; 
Kitani et al, 1994; Thiffault et al., 1995). This implied that L-deprenyl may exert its 
effect through inhibition of MPTP conversion as well as the removal of O2'-. 
1.4.2 Hydrogen Peroxide (H20 2), Catalase and Glutathione (GSH) 
Oxidative deamination by MAO or autoxidation of dopamine both contribute 







F~2+ ~02--~==========~--~>~~O c- )1 Catalase, GSH-Px 
Fe3+~l 
OH· 
,,""---~>~ Lipid Peroxidation -~>~ Cell death 
Fig. 4 Mechanisms of reactive oxygen species generation and scavenge by anti-
oxidants in eNS 
Dopamine + H20 + O2 MAO) 3,4-Dihydroxyphenylacetaldehyde + NH3 + H20 2 
H20 2 can act as an oxidizing agent and is also a precursor for the highly 
oxidizing and tissue-damaging free radical, hydroxyl (OH). 
Under normal condition, H20 2 is removed by the action of two types of 
enzyme, catalase and selenium-dependent glutathione peroxidase. H20 2 reacts with 
reduced GSH to fonn oxidized glutathione (GSSG) and water, catalyzed by the 
enzyme glutathione peroxidase (GPx). Reduced glutathione is regenerated by the 
action of glutathione reductase (GSH-Rd) (Meister and Anderson, 1983). 
GSH-Px 
2GSH + H20 2 ) GSSG + 2H20 
GSH-Rd 
GSSG + NADPH + H+ ---~) 2GSH + NADP+ 
CAT 
Since GSH-Px is more abundant than catalase in the brain, it is probably a more 
important enzyme for the scavenging of H20 2 in the CNS (Marklund et al., 1982). 
1.4.3 Hydr~xyl Radicals (OH) 
H20 2 reacts with ferrous (Fe2+) ions to fonn (OH) radical by the Fenton 
reaction. 
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OH' reacts rapidly with almost every molecule found in living cells, including 
DNA (causing strand breakage and chemical alterations of the deoxyribose and of the 
purine and pyrimidine bases), membrane lipids and carbohydrates (Floyd and Camey, 
1992). OH' is capable of initiating the process of lipid peroxidation by abstracting a 
hydrogen atom from a polyunsaturated fatty acid (PUFA) side chain (lipid-H) in 
membrane lipids leading to the formation of peroxyl radicals. The peroxyl radicals can 
attack membrane proteins (therefore damaging receptors and enzymes) and can also 
abstract hydrogen atoms from adjacent fatty acid side chains. The presence of lipid 
peroxides within a membrane severely disrupts its function, altering fluidity and 
allowing ions such as Ca2+ to leak across the membrane and contributing to 
Ca2+ -dependent cytotoxicity (Borg, 1993). The presence of high amounts of OH' is 
potentially dangerous to the CNS since the brain has a high reservoir of PUFA. 
Adams et al. (1993) demonstrated that H20 2 and OH' were also products of the 
interaction of MPP+ with mitochondrial complex I, further implicating the role of 
oxidative-induced injury as a cause of PD. 
1.4.4 Nitric Oxide (NO) 
Nitric oxide (NO) is a byproduct during the synthesis of L-citrulline from 
L-arginine by nitric oxide synthase (NOS). 
NOS 
L-arginine -----~) L-citrulline + NO 
Three major isoforms of NOS have been identified and cloned: neuronal 
(nNOS), endothelial (eNDS) and inducible (iNOS) NOS. The nNOS and eNDS are 
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constitutively expressed and are calcium/calmodulin-dependent (Bredt et al., 1991; 
Lamas et al., 1992), while iNOS expression requires appropriate stimulation by several 
factors such as cytokines, for example, tumor necrosis factor-a and/or interleukin-1~ 
plus interferon-y (IFN-y) (Hewett et al., 1993; Murphy et al., 1993; Egberongbe, 
1994). Cytokine-activated iNOS expression is mediated by nuclear transcription factor 
kappa-B (NF1d3) (Mulsch et al., 1993; Xie et al., 1994; Schini-Kerth et al., 1994). 
NF1d3 comprises of 2 subunits, (often p50 and p65) and is normally present in the 
cytoplasm in an inactive form bound to I1d3. Upon activation, NF1d3 will dissociate 
from I1d3 and migrate into the nucleus where it binds to the iNOS promoter region and 
initiate gene transcription (Fig 5). iNOS induction was shown to require NF1d3 
activation and the ability of NO itself to down-regulate iNOS expression (Griscavage 
et al., 1993; Park et al., 1994) has also been attributed to inhibition of NFKB activation 
(Colasanti et al., 1995; Peng et al., 1995). 
NO is an inorganic molecule with many physiological functions (Moncada et 
al., 1991). In the nervous system it can act as a neuronal messenger but, in situations 
of excessive production, may become neurotoxic (Dawson et al., 1992). In line with 
this, NO has been suspected of being one of the many sources of toxic free radicals in 
the brain, since it can react with 02"- at physiological pH leading to the formation of 
peroxynitrite anion (ONOO-), which is an extremely reactive molecule and a powerful 
oxidant (Beckman et al., 1990). 
ONOO- can further oxidize some important intracellular targets e.g. thiols and 
zinc finger (Radi et al., 1991a), as well as leading to DNA breakage, activation of poly 
(ADP-ribose) synthetase, and cellular energy depletion (Salgo et al., 1995; Szabo et 
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Transcriptional Control of iNOS 0 ~ 
Dexamethasone.-----fll EB 
"'--2) 
Fig.5 : Transcriptional control of iNOS. Tumor necrosis factor (TNF) or 
interleukin-l (IL-I) when bound to extracellular receptors of the 
cells will activate the tyrosine kinase. It then phosphorylate the 
NFKB-IKB complex (Inactive fonn). This will lead to dissociation 
of NFkB from IkB. NFkB is then translocated into the nucleus 
which will bind to the iNOS promoter region and initiate the 
mRNA transcription. After translation, iNOS protein formed will 
start to produce substantial amount of NO. 
al., 1996) (Fig 6). ONOO-can also decompose to form the powerful and cytotoxic OH-
and to nitrogen dioxide (N02) spontaneously, which are potent activators of lipid 
peroxidation (Beckman et al., 1990; Radi et al, 1991b; Crow, et al., 1994) (Fig 7). 
ONOO- + H+ ~ HOONO ~ 'HO- + N02' 
NO has the ability to diffuse through cell membranes. It can bind to the haem 
iron of guanylyl cyclase (GC), activates it and generate cGMP from GTP (Bredt and 





GTP ------+) cGMP 
The NO-haem-guanylyl cyclase system represents an unique signal transduction 
mechanism linking extracellular stimuli to the synthesis of cGMP in nearby target cells. 
In this system it is suggested that cGMP acts as a second messenger. It regulates 
cGMP-dependent protein kinases, sensory and peripheral cGMP-gated ion channels, 
cGMP-stimulated or inhibited cyclic nucleotide phosphodiesterases (Schmidt et al., 
1993). This NO/cGMP signaling also includes several other important second 
messenger molecules, including cAMP and free Ca2+; the latter is modulated by cGMP 
either directly or indirectly via inositol trisphosphate (IP3), 1,2-diacylglycerol (DAG), 
cyclic ADP ribose (cAD PR) , and other lipid-derived messengers (e.g. eicosanoids) 
(Schmidt and Walter, 1994). 
Furthermore, NO has been shown to inhibit the function of the mitochondrial 
respiratory chain and disrupt normal cellular iron homeostasis (Reif and Simmons, 
1990; Bolanos et al., 1994). Evidence so far has shown that NO affects only 
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Fig.6 Mechanisms of NO-mediated neurotoxicity. Excitotoxicity, i.e., 
neurotoxicity by excessive exposure of neurones to glutamate 
is, at least parti,ally, NO-mediated. The possible mechanisms 
leading to neuronal ~ell death involve ONOO- formation and, 
in general, it is accepted that energy failure is a key factor. 
Thus ONOO- InItIates unspecific protein and lipid 
peroxidation, DNA damage with activation of the energy-
consuming repair system involving poly(ADP-ribose) 
synthetase (PARS), inhibition of the mitochondrial respiratory 
chain. iNOS induction in glial cells may also have a relevant 
contribution to NO-mediated neurotoxicity. Induction of iNOS 
is triggered by LPS in astrocytes. Either NO or ONOO-
inhibits mitochondrial respiratory chain in astrocytes, but these 
cells compensate by switching to glycolysis to maintain energy 
homeostasis. However, as NO and ONOO- are highly 
diffusible, these compounds may cause cell toxicity in the 
neighbouring neurones. 







Fig. 7 Metabolism of NO. NO is synthesized by NOS which forms 
NO and L-citrulline from L-arginine. NO is degraded rapidly 
because of its reactions with O2 or °2'-, Thus, the NO reaction 
with O2 forms NO~ which is converted further into nitrite 
(N0i) and nitrate (N03 -); nitrous acid (N203), which is 
degraded further to N02 -; finally, NO reacts with °2'- to form 
the peroxynitrite anion (ONOO-), which is a powerful oxidant 
that may decompose further, on protonation, to the hydroxyl 
radical (OH.) and N02. OH' and N02 can react to fonn nitric 
acid, but this occurs at a lower rate than other reactions of OH'. 
This figw.e is used by the courtesy of 80131105, l.P. from l. Neurochem. 68 (199S) 
"""-, 
1994). However, in view of the recent finding that inhibition of complex IV is 
necessary to induce irreversible inhibition of complex I (Cleeter et al. 1994), the role of 
NO production in affecting mitochondrial function may be important in the 
pathogenesis of PD. Apart from this, NO can also bind to and inhibit such enzymes as 
aconitase (Liew and Cox, 1991; Welsh and Sandler, 1992) and other P-450 enzymes 
(Wink'et al., 1993). 
Stroke, other neurodegenerative diseases (like Alzeheimer's disease), neural 
regulation of smooth muscle" including peristalsis, and penile erection are also 
associated with NO. It is also responsible for endothelium-derived relaxing factor 
(EDRF) activity in the regulation of blood pressure. 
Recently, NO was proposed to play a role in the oxidative stress and in the 
pathogenesis of neurodegeneration in PD. This is supported by NO's ability to release 
iron from ferritin, inhibition of the mitochondrial respiratory chain and the subsequent 
formation of free radicals (Reif and Simmons, 1990; Lancaster, and Hibbs, 1990; 
Youdim et al., 1993; Bolanos et al., 1994; Cleeter et al., 1994). These could lead to 
neuronal cell death. The iron reductant neurotoxin 6-hydroxydopamine (6-0HDA), 
which induces PD in animals (rodents and primates), also releases ferritin-bound iron 
(Monterio and Winterboume, 1989) - and initiates calcium-dependent oxygen free 
radical induced lipid peroxidation (Heikkila and Cohen, 1972; Cohen and Heikkila, 
1974; Sachs and Jonsson, 1975; Monterio and Winterboume, 1989). These findings 
provide a very attractive hypothesis for the role of NO in the pathogenesis of PD, 
given the possible reaction between NO and O£ and its ability to release iron and 
ferritin from the iron-rich SN. 
Qureshi et al., (1995) further showed that there was an increase in the 
cerebrospinal fluid concentration of nitrite, a metabolite of nitric oxide, in PD patients. 
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In the MPTP-induced Parkinsonian model, Smith et al. (1994) showed that by 
inhibiting NOS, MPP+- and MPTP-induced toxicity in Sprague-Dawley rats can be 
attenuated. Further to this, Schulz et al., (1995a) showed that inhibition of nNOS by 
7-nitroindazole (7-NI) reduced MPTP toxicity to doparninergic neurons. Other than 
inhibition of nNOS, 7-NI also inhibits iNOS though to a lesser extent. These authors 
showed that NO appeared to be necessary for hydroxyl free radical generation in MPP+ 
toxicity. 
Pretreatment of mice with FK-506, a novel immunosuppressant, significantly 
protected MPTP-induced DA depletion in the striatum, but FK-506 itself did not affect 
the DA content (Kitamura et al., 1994). These authors also showed that cyclosporin A 
(CsA), another ~unosuppressant, protected MPTP-induced DA depletion. It was 
thus suggested that immunosuppressants can inhibit nNOS and protect MPTP toxicity 
towards the nigrostriatal doparninergic neurons of young C57BL/6 mice. However, it 
is still unclear how the inhibition of nNOS can protect against MPTP-induced toxicity. 
So far, there is such convincing evidence suggesting that NO may be involved 
in the pathogenesis of PD. The source of this NO production is still, however, 
unknown. 
1.5 Astrocytes 
1.5.1 Chara,cteristics of astrocytes 
Astrocytes are the major constituents of macroglia and the most abundant cell 
type in the CNS. Morphologically, astrocytes can be classified into two types: 
protoplasmic and fibrous. Protoplasmic astrocytes are characterized by thick, branched 
processes with spiny projections and they are mainly localized in the gray matter. In 
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contrast, the fibrous astrocytes have relatively thin processes with few branches and 
are primarily localized in the white matter (Guroff, 1980). 
Astrocytes contain characteristic biochemical markers. They can be identified 
immunohistochemically by the presence of glial fibrillary acidic protein (GFAP), the 
subunits of glial-specific intermediate filaments (Eng et al. 1971; Dahl and Bignami, 
1973) .. As a result, GFAP is commonly used as an astrocyte marker for both in vivo 
and in vitro studies . Other markers of astrocytes include the enriched protein S-100 
(Hyden and McEwen, 1966; Hansson et al., 1980, 1984) and glutamine synthetase 
(Martinez-Hemandez et al., 1977; Hallermayer et al., 1981). 
Astrocytes provide many metabolic and supporting functions to. neurons. They 
also appear to signal to neurons through the activation of neuronal NMDA receptor 
via the release of the neurotransmitter glutamate and subsequent increase in neuronal 
Ca2+ level (Parpura et al., 1994). 
Astrocytes are known to contain MAO-B (Levitt et al. 1982), for the 
metabolism of mo no amines , and large amounts of antioxidants such as GSH, 
CuZn-SOD, Mn-SOD and catalase (Hirsch, 1992). Astrocytes have, therefore, an 
important role to play in the defense mechanism against oxidative stress in the CNS. 
1.5.2 The Role of astrocytes in PO 
The presenc~ of glial scars in parkinsonian brains is a common phenomenon 
and thought to be the result of rapid proliferation of astrocytes to fill up the space left 
by nerve cell loss (Fomo et al. 1992). They are usually localized in the areas most 
severely affected by neurodegeneration (i.e., lateral and ventral portions of the zona 
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compacta of the 'SN) (Fomo et al., 1992). It was thus suggested that astrocytes may 
play a passive role, secondary to the neuronal loss in PD. 
However, increase of biochemical and physiological knowledge of astrocytes, 
and given their close relation with neurons, astrocytes seem to participate more 
actively in the process of neuroprotection and neurodegeneration than previously 
thought. Astrocytes contain relatively high concentrations of GSH and GSH-Px when 
compared to neurons (Slivka et al. 1987; Raps et al. 1989). The presence of high GSH 
levels in these cells suggested that astrocytes are the major site for H20 2 detoxification 
in theCNS and thus protecting them as well as neighbouring neurons from 
oxidative-induced injury. In contrast, the lack of GSH in neurons renders them reliant 
on nearby astrocytes for protection against H20 r induced damage. 
It was recently reported in normal human postmortem brains that the density of 
GSH-Px positive astrocytic-like cells was higher in the vicinity of the dopaminergic cell 
groups in the mesencephalon known to be resistant to the pathological process of 
Parkinson's disease, while the area surrounding the dopaminergic neurons that were 
most vulnerable to PD had a low density of GSH-Px positive astrocytic-like cells 
(Damier et al., 1993). Thus, the amount of GSH-Px-containing astrocytes may be 
critical for a protective effect against oxidative stress in the SN. 
As previously mentioned, MAO-B takes part in the catabolism of dopamine 
and is located predominantly in astrocytes (Levitt et al. 1982; Westlund et al. 1985). 
ROS are produced during dopamine oxidation (Fig 4). In fact, the rate of ROS 
production was largely determined by the MAO-B activity. Moreover, changes in glial 
MAO-B activity may affect dopamine content of the nigrostriatal system as well. A 
significant increase in MAO-B activity was observed in older humans and animals 
(Robinson et al. 1971; Benedetti and Keane, 1980; Irwin et al. 1992). An increase in 
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glial MAO-B activity may lead to a higher rate of dopamine turnover and a consequent 
increase in ROS· production. Thus, the involvement of astrocytes in dopamine 
catabolism not only contributes to the loss of dopaminergic activity observed in 
Parkinson's disease, but may also explain, at least in part, the role of aging as a risk 
factor for parkinsonism (Kurtland et al. 1973). 
Complex I deficiency was found in the postmortem brain of PD patients. 
Similarly, MPTP can also induce mitochondrial complex I inhibition in neurons as well 
as astrocytes. However, astrocytes are more resistant to MPTP-induced ATP 
depletion. This may be due to astrocytes having an alternative pathway of energy 
production. Di Monte et al. (1992a) demonstrated that a relatively early event of 
MPTP-induced toxicity in astrocytes was the increase in consumption of glucose and 
lactate production, with a glucose/lactate ratio of 1.85:1. This value is close to 2 
suggesting that the major metabolic pathway is shifted to glycogenolysis. These cells 
can utilize the accumulated energy substrate, glycogen (Guth and Watson, 1968; 
Cataldo and Broadwell, 1986), in conditions of energy crisis. Glycogenolysis may be 
activated in astrocytes in order to sustain energy demand (Magistretti et al. 1986). 
During MPTP-induced injury there was a decrease in ATP level (Chan et al., 1992) 
and, therefore, the role of astrocytes as an energy source for neurons (Kuffler et al., 
1984) may be critical. 
Another possible hypothesis of dopaminergic degeneration in PD is glutamate 
toxicity. Astrocytes, contain glutamine synthetase (GS) (Martinez-Hernandez et al., 
1977) which can convert glutamate to glutamine after imported via a high-affinity 
uptake system (Hertz, 1979). Therefore, if neuronal damage is related to an increased 
release of excitatory amino acids and/or an increased sensitivity of NMDA receptors to 
excitatory amino acids, the effects of MPP+ neurotoxicity may depend on the ability of 
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astrocytes to modify the extracellular concentrations of glutamate. Astrocytes may 
protect against MPP+ -induced excitotoxic injury by scavenging glutamate from the 
extracellular space, thereby reducing the exposure of NMDA receptors to this 
excitatory amino acid. Failure or insufficient GS in astrocytes can lead to activation of 
NMDA receptors on neurons, or increase in neuronal intracellular Ca2+ as well as 
induction of nitric oxide production. 
Nitric oxide is implicated in Alzheimer's disease (Ii et al., 1996), mUltiple 
sclerosis (Sherman et al., 1992) and AIDS dementia (Adamson et al., 1996). Recent 
findings showed that PD might also be associated with NO. Hunot et al. (1996) 
showed that there was an increase in the density of NADPH-diaphorase-positive glial 
cells in the mesencephalon of parkinsonian postmortem brains. These cells were also 
shown to be iNOS positive. The authors suggest an increased density of glial cells 
(activated macrophages or astrocytes) expressing iNOS in the altered dopaminergic 
cell groups in PD was likely to occur in association with neuronal injury. However, the 
cause and effect of iNOS induction in these PD brains needs further investigation. 
1.6 The aim of this project 
Although NO has been ,implicated in DA neuronal degeneration in the 
substantia nigra pars compacta (SNc) in patients with PD (Smith et al., 1994; Schulz et 
al., 1995a; Hunot et al., 1996), the cause or effect of NO in the pathogenesis of PD is 
still far from clear. 
Recent studies showed that using the nNOS inhibitor 7-NI, MPTP-induced 
neurotoxicity was blocked, thus implying neurons as a source of NO production in PD 
(Schulz et al., 1995a; pzedborski et al., 1996; Hantraye et al., 1996). Although the 
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results generated much interests, the mechanism whereby this nNOS inhibition in 
ameliorating toxicity are not clear. Recently, Castagnoli et al. (1997) showed that 7-NI 
in fact inhibited MAO-B production, thus implicating the protection against 
dopaminergic neurotoxicity was through the blocking of MPTP conversion to MPP+ 
rather than through the blocking of NO production. This result suggested that the 
source of NO may not be confined to neurons alone. 
Since Hunot et al. (1996) showed that only iNOS positive glial cells were 
present in the SNc in PD postmortem brains, glial cells instead of neurons may be the 
primary source of NO production seen in PD or MPTP-induced toxicity. However, 
Hunot et al. did not confirm whether the iNOS positive glial cells observed were 
astrocytes or microglia, thus the source of NO production from glial cells still awaited 
further clarification. The aim of the project is therefore to ascertain whether astrocytes 
are a source of NO production after MPTP treatment. 
To achieve this goal, astrocytes were cultured from the cortex (with the 
removal of frontal cortex), striatum and ventral mesencephalon of neonatal C57/BL6 
mice and then treated with MPTP. Ventral mesencephalon was selected because this is 
the' region where the dopaminergic neuronal cell bodies are situated. Striatum is the 
location of the dopaminergic axon, terminals and cortex was selected to serve as a 
non-dopaminergic control. 
Previous r~sults from our laboratory have already showed that astrocytes from 
various brain regions had different levels of aSH and they responded differently to 
MPTP-induced toxicity (unpublished data). In these studies, cultured mesencephalic 
astrocytes were shown to be more vulnerable to oxidative stress because aSH content 
was the lowest in these astrocytes and aSH was depleted most rapidly after MPTP 
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treatment. To be in line with previous findings from our laboratory, the present study 
therefore also utilized astrocytes cultured from ventral mesencephalon, striatum and 
cortex. 
In order to examme whether NO is produced in astrocytes after MPTP 
treatment, extracellular nitrite and nitrate, as well as intracellular cGMP levels were 
measured. To further determine whether the NO produced was due to NFlCB-activated 
iNOS induction, immunocytochemical staining using NFlCB anti-p65 subunit antibody 
was performed. It is because iNOS induction, in some cases, requires the activation of 
NFKB. 
A decrease in SOD activity will leave more 02"- in the cells. Excessive 02"-
reacts with NO rapidly to form the highly reactive ONOO- (see section 1.4.4). SOD 
was also shown to increase in the postmortem PD brain (Saggu et al., 1989; Marttila et 
al., 1988), suggesting that there was also an increase in 02"- formation in PD. SOD 
activity was therefore also examined in the present study. Since 02"- is unstable, and as 
a result, cannot be measured accurately, SOD levels were used as an index for the 
amount of O£ released. It is hoped that the present study will further shed light into the 
source of NO production during MPTP-induced toxicity and thus further clarify the 
role of NO in the pathogenesis of PD. 
26 
CHAPTER 2-: MATERIAL AND METHODS 
2.1 Astrocyte cultures 
1-day-old neonatal C57BL/6 nnce provided by the animal house of the 
Chinese University of Hong Kong were used in this project. All the procedures were 
carried out under strict sterile conditions. Animals were killed by decapitation and 
heads rinsed with 70% alcohol. The brains were removed under a dissection 
microscope and cerebral cortices (without frontal cortices), striatum and ventral 
mesencephalon were dissected free of meninges (Fig. 8). Brains were minced into 
small pieces in cold sterile Ca2+- and Mg2+-free Hank's balanced salt solution (HBSS, 
supplemented with 15 mM HEPES and 0.35g sodium bicarbonate in 1L, pH7.4, 
Gibco). The brain tissues were trypsinized in 0.125% trypsin solution (1:1 voVvolof 
0.25% trypsin solution: HBSS) for 10 min at 37°C. This reaction was stopped by the 
addition of equal volume of serum-containing medium The suspension was 
centrifuged at 1800 rpm for 3 min (Centaur 2, MSE) and the pellet was resuspended 
and dissociated through a 18~ gauge needle and syringe. The cells were further 
dissociated by passing through a 70pm pore size sterile nylon Nitex sieve (Spectrum 
Medical Industries Inc.). Cell viability was measured using trypan blue (Sigma) (Philip, 
1973) and the total number of cells were counted on a haemocytometer. The mixture 
was diluted to a plating density of 1x107 cellsn5 cm2 culture flask (Falcon, Becton 
Dickinson & Company). After seeding, the cells were incubated in a humidified 
incubator under 5% CO2 / 95% air at 37°C. The culture medium was changed after 
three days of seeding and subsequently twice weekly. The culture medium is composed 
of Dulbecco's modified Eagle's medium containing Ham's nutrient mixture F-12 
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Fig. 8: Astrocyte cultures. "'<0-
Mter decapitation, the brain was cut along the dotted lines under a 
dissecting microscope (a). Frontal cortex was discarded since it 
contains dopaminergic terminals. From the anterior view of the brain 
with frontal cortex removed, striatum (St) can be seen and dissected 
out easily (b). With the removal of the hippocampus, thalamus and 
other structures, cerebral cortex was collected. The midbrain was 
oriented so that the dorsal part of mesencephalon as well as the 
cerebellum can be dissected away from the ventral part (horizontal 
dotted line) (c). Mter dissecting the hypothalamic nuclei (central V 
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(DMEMJF12, Gibeo) supplemented with · 10% heat inactivated fetal bovine serum, 1 % 
penicillin (1,000 unit/ml) and 1 % streptomycin (1,000 pg/ml). 
After 12 to 14 days of incubation, when the cells became confluent, microglia, 
oligodendrocytes and other non-adhering cells were removed by shaking at 260 rpm 
overnight in 37°C (Lab-Line Orbit Envrron-shaker). After shaking, the non-adhering 
cells were removed and the attached cells, which consisted mainly of astrocytes (Fig. 
9), were washed twice with HBSS. 
Prior to biochemical assays, the astrocytes were subcultured onto 35-mm 
tissue culture dishes (Falcon, Becton Dickinson & Company) for five days in 
serum-containing medium at a plating density of 4x105 cells/dish. Immunostaining of 
cultures with antibodies to glial fibrillary acidic protein (GFAP) revealed that over 
95 % of the cells were astrocytes and the remaining cells being microglia and 
oligodendrocyte (results not shown). 
2.2 M PTP treatment 
Cultured astrocytes from the cortex, striatum and ventral mesencephalon were 
treated with 500pM MPTP (Research Biochemicals International, Natick, MA, 
U.S.A.) in serum-free medium and then incubated for 72 h (Fig 10). 500pM was a 
dose previously determined in our laboratory to be a sublethal dose that can induce 
metabolic changes in astrocytes. This is similar to the dose used by Di Monte et al. 
(1991) in primary cultures of mouse astrocytes. At incubation time points of 0, 4, 8, 
12, 24, 48 and 72 h, samples were collected for biochemical assays. The culture media 
was collected for lactate dehydrogenase (LDH) assay to assess cell viability or for 
nitrite and nitrate measurements. The cells were then lysed and homogenized for 
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Fig. 9: Phase contrast micrographs of C57IBL6 mouse astrocytes 





Fig. 10: Phase contrast micrographs of C57IBL6 mouse astrocytes after 72 h ~-..... -




superoxide dismutase (SOD) or cyclic guanosine 3',5' monophosphate (cGMP) 
determination. 
2.3 Lactate Dehydrogenase Assay 
LDH is secreted from the cells to the culture medium when the cells are 
undergoing increased activity of glycolysis due to failure of the mitochondrial A TP 
formation. Thus, measuring the LDH activity of the culture medium of the astrocytes 
after MPTP treatment would reflect the metabolic state of the cells. The measurement 
of the LDH activity was according to the method of Amador et al. (1963). The 
principle of the assay is based on LDH catalyzing the oxidation of lactate to pyruvate 
with simultaneous reduction of nicotinamide adenine dinucleotide (NAD) and is shown 
as follows: 
LDH 
Lactate + NAD ----~) Pyruvate + NADH + H+ 
The formation of the reduced nicotinamide adenine dinucleotide (NADH) 
results in an increase in absorbance at 340 nm which is directly proportional to LDH 
activity in the sample. During 0, 4, 8, 12, 24, 48 & 72 h after MPTP treatment, culture 
media were removed, and 50f.l1 of medium were mixed with 1 ml pre-warmed (30°C) 
LD-L regent [LDH-L 50 kit (Sigma Diagnostics®, Sigma)]. Activity of LDH was 
measured spectrophotometrically (Beckman DU-7S00) at 340 nm in 30°C. 
The reaction was left to stand for 30 second and the initial reading was 
recorded. The reaction mixture were further incubated for 60 seconds and the final 
reading was recorded. The change of absorbance (i\A) per minute (LVrnin) was 
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obtained by subtracting the initial reading from the final reading. The determination of 
the LDB activity (UIL) is according to the following equation: 
t:,.A per min x Total reaction volume x 1000 
LDB Activity (UIL) = ----------------
6.22 x sample volume x light path 
where "t:,.A per min" represent the change in absorbance per minute at 340 run; total 
reaction volume is equal to 1.05ml; sample volume is 0.05ml; coefficient of extinction 
of NADB is 6.22; light path is 1 cm; and 1000 is the factor to convert units per ml to 
units per liter. 
t:,.A per min x 1. 05 x 1000 
LDB Activity (UIL) =---------
6.22 x 0.05 
= t:,.A per min x 3376 
One unit of the LDB activity is defined as the amount of enzyme that will catalyze the 
formation of one micromole of NADB per minute under the conditions of the assay 
procedure. 
LDB released into the culture medium was assayed as an index for astrocyte 
viability during the 72 h MPTP treatment. Each time point required 3 dishes, and 5 
independent experiments were performed for the 7 time points. 
2.4 Determination of nitrite and nitrate levels in cultured astrocytes 
Nitric oxide (NO) will degrade rapidly (half-life,..., 5 seconds) (Dawson and 
Synder, 1994) to form nitrite and nitrate when reacting with oxygen and 02'-
respectively (Schmidt et al., 1992) (Fig 7). Measuring the amount of nitrite and nitrate 
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can therefore inclirectly reflect the level of NO. To achieve this, nitrate was first 
reduced to nitrite by nitrate reductase (Schmidt et al., 1992). The total nitrite level was 
then determined spectrophotometrically using the Griess reaction and a microplate 
reader (Schmidt et al., 1992). For nitrate reduction, samples were centrifuge at 1000 x 
g for 15 min at room temperature to remove cells and debris. All subsequent 
incubations were performed in red polypropylene tubes to protect against 
light-sensitive nitrate reductase. Nitrate was reduced stoichiometrically to nitrite by 
incubating 150 JlI sample aliquots for 15 min at 37°C in the presence of 0.1 unit/ml 
nitrate reductase (from Aspergillus species; Boehringer Mannheim), 50 JlM NADPH, 
and 5 JlM FAD in a final volume of 160 Jll. When nitrate reduction is complete, 
NADPH is oxidized with 10 units/ml lactate dehydrogenase (from rabbit muscle; 
Boehringer Mannheim) and 10 mM sodium pyruvate to avoid interference with nitrite 
determination. Samples were incubated for 5 min at 37°C in a final volume of 170 Jll. 
Total nitrite level was determined spectrophotometrically by using the Griess 
reaction (Griess, 1864). After nitrate reduction, samples were cooled down to 4°C. 1 
mM sulfanilamide and then 0.1 M HCI was added to a final volume of 200 JlI 
(diazotization). This was followed by centrifuging samples at 1000 x g for 15 min at 
4°C. An aliquot of 150 JlI of each supernatant fraction was transferred to 96-well 
microtiter plates, and the plates read at 540 nm. From the absorbance in each well, the 
averaged absorbance of a row of wells containing 150 JlI of water is subtracted to give 
absorbance value Al (blank). 10 JlI of 1 mM of naphthylethylene-diamine was added to 
all the sample wells including the blank, and incubated at room temperature for 10 min 
before the plates were read again (to let the product of diazotization react with 
naphthylethylene-diamine to form an azo derivative), subtracting the blanks (Al) to 
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-give the absorbance value A2. A2 - Al plotted against known nitrite concentrations 
(standard nitrite) give the standard curve. Nitrate and nitrite amounts in the samples 
were read from the standard curves. 
2.5 Assay for Cyclic GMP production 
. NO was shown to be capable of binding to the haem iron in soluble guanylyl 
cyclase to activate the enzyme and elevate cGMP (Schmidt et al., 1993). Astrocytes 
also showed elevated cGMP levels in response to NO (De Vente and Steinbusch, 
1992). Although little is known of the consequences of this cyclic nucleotide 
specifically in these cells, cGMP is widely used to reflect the intracellular level of NO. 
Prior to cGMP measurement, astrocytes were washed three times in 1.0 ml of Earle's 
Balanced Salt Solution (EBSS, 117 mM NaCl, 5.3 mM KCl, 26 mM NaHC03, 1 mM 
NaH2P04·H20, 1.5 mM CaCh, 1.5 mM MgS04, and 25.6 mM glucose) and 
equilibrated in this buffer for 20 min at 37°C. Fresh buffer containing 0.6 mM 
isobutybnethylxanthine (IBMX, a broad-spectrum phosphodiesterase inhibitor), 20 
U/ml superoxide dismutase (superoxide scavenger), and 100 JlM L-arginine (substrate 
for nitric oxide synthase) was added. Cells were incubated at 37°C for an additional 20 
min. The incubation buffer was then removed and replaced with a small volume of 
ice-cold 50 mM sodium acetate containing 0.6 mM IBMX, and the plate was 
snap-frozen in liquid N2 vapour. Cells were immediately scraped from the culture 
plates and assayed for cGMP using a radioimmunoassay (RIA) kit (Amersham, U.K.). 
Acetylation of standards and samples were performed prior to the assay in order to 
obtain a higher sensitivity. The results were expressed as fmole/dish. 
Three culture dishes were needed for each time point and cGMP was measure 
twice in a single independent measurement. 
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2.6 Inhibition of NO by L-NAME and Dexamethasone 
Since nitrite and nitrate can be produced from other sources, it was necessary 
to identify their source. NG-nitro-L-arginine methyl ester (L-NAME) is a L-arginine 
analo g which can compete with L-arginine for the NOS active site to prevent 
production of NO. This compound inhibits all 3 isoforms of NOS (Gozal et al., 1996). 
100JlM of L-NAME was added together with 500 JlM MPTP in serum free medium to 
detennine whether NOS is responsible for generating the nitrate and nitrite. 
Dexamethasone, a glucocorticoid, is suggested as a preferential inhibitor of 
iNOS (Knowles et al., 1990; Simmons and Murphy, 1993). Although it was shown 
that astrocytes contain mostly iNOS (Galea et al., 1992; Simmons and Murphy, 1993), 
iNOS and nNOS had been reported to be co-localized in astrocytes of certain regions 
like cerebellum In the present study, it is uncertain whether both iNOS and nNOS 
were also co-localized in astrocytes from cortex, striatum and mesencephalon, 
Dexamethasone (lJlM) was therefore added together with 500JlM MPTP and 
incubated in the astrocytes in order to ascertain whether the effects of NO produced in 
this study are due to the activation of iNOS. 
Three dishes were required for each time point of each NOS inhibitor and three 
independent experiments were done. 
2.7 NFKB immunostaining 
Primary astrocytes, after shaking, were subcultured onto poly-L-Iysine-coated 
4-well Lab-Tek chamber slides (Nunc Inc., USA) with a seeding density of 8 x 104 
cells/well and grown for 5 days in DM/F12 medium with 10% FBS. 0.5 ml of 500JlM 
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MPTP in serum free DM/F12 medium was added at 0, 4, 8, 24, 48 h. LPS-treated 
astrocytes (10~g/ml, 6 h treatment) was used as the positive control and cells without 
primary antibody addition was used as a negative control. Cells were washed twice in 
ice-cold PBS, fixed 1 h at room temperature in 4% paraformaldehyde in O.lM 
phosphate buffer, pH7.2, washed twice in PBS again. Fixed cells were then incubated 
with~ anti-NFKB p65 antibody (1:200 dilution, Santa Cruz Biotechnology, Inc.) 
containing 0.1 % Triton X-lOO, 0.1 % BSA and 0.05% NaN3 (PBSTB) overnight at 
room temperature. The cells were washed 3 times in PBS and incubated with 
biotinylated secondary antibody [Vectastain ABC Kit, rabbit IgG, PK 6101; dilution 
1:500] in PBSTB for 2 h at RT. Cells were washed in PBS and incubated in 
avidin-biotinylated horseradish peroxidase in PBS for 1 h at room temperature then 
washed in PBS. The reaction sites were then visualized by the glucose 
oxidase-diaminobenzidine (DAB)-nickel procedure (Shu et al., 1988). The cells were 
preincubated with ammonium nickel sulfate-DAB solution for 10 min and then glucose 
oxidase solution was added. The reaction sites were shown in a dark blue color, the 
cells were not counter-stained in order not to mask the dark blue nuclear staining. 
Cells were dehydrated in an alcohol series, cleared with xylene and mounted with 
mountant (Permount SP15-500, Fisher Scientific). Cells were observed under 
photomicroscopy (Zeiss, Germany) 
2.8 Superoxide Dismutase (SOD) Assay 
SOD activity in astrocytes after MPTP treatment was measured according to 
-. McCord and Fridovich (1969), with modifications (Crapo et al., 1978). After the 
removal of culture medium for LDH activity, intact cells were scraped off the culture 
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plates into 2 ml eppendorff tubes. Cells were then homogenized in 5 ml of distilled 
water. 80pl of the homogenates was used for the measurement of protein content 
(Lowry et al., 1951). The remaining homogenates was centrifuged at 10,000 rpm for 
SOD assay. SOD activity was measured at 25°C in 50 mM phosphate buffer (2.4 ml), 
pH 7.8, containing 0.1 mM EDTA. The reaction mixture consisted of 0.3 ml 
cytochrome c (0.1 mM) (Sigma C-7752) and 0.3 ml xanthine (0.5 mM) (Sigma 
X-7375), making a final volume of 3 ml. Potassium cyanide (3 mM) was added to the 
incubation medium to inhibit cytochrome c oxidase and cytochrome c peroxidase 
activities which can falsify SOD activities. Prior to sample measurement, xanthine 
oxidase (EC 1.1.3.22, Sigma X-1875) was diluted to give a reading of 0.02 per min 
rate of cytochrome c reduction at 550nm by spectrophotometer (Beckman DU-7000). 
For the sample measurement, half of the medium (1.2 ml) was replaced with an equal 
volume of cell homogenates. SOD activity in cell homogenates was assayed as the 
ability of the cells sample to inhibit a 02°--driven reaction. One unit of SOD is defined 
as the amount of SOD required to inhibit 50% of cytochrome c reduction. This unit 
represented the total SOD activity (CuZn-SOD and Mn-SOD). The rate of change of 
enzyme activity was calculated from the slope of the rate of cytochrome c reduction 
and expressed as U/mg protein/hour. ' 
In this experiment, at 0, 4, 8, 12 and 24 hours, 7 x 35 mm plates of cultured 
astrocytes from each region were used. Four to six independent SOD assays were 
performed for each time point and for each treatment and control groups. 
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2.9 Statistics 
All the data are expressed as the mean + standard error (SEM). One Way 
ANOVA followed by post-hoc Dunnett's test was used for nitrite measurements. 
Post-hoc Student-Newman-Keuls test was used for statistical analysis of SOD 
activities. p values <0.05 are considered as significant. 
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CHAPTER' 3 RESULTS 
3.1. Lactate dehydrogenase (LDH) activities after MPTP 
treatment 
500pM MPTP-treated astrocytes showed minimal elevation of LOH in the 
culture medium during the initial 24 h of incubation (Fig. 11). However, by 48 h of 
incubation, a rapid increase in LOH activity was observed in cells from all three 
regions. LOH activity in cortical astrocytes showed a 17 fold increase (19.3 + 4.74 
U/L) by 48 h of incubation when compared with that of the control (1.11 + 0.55 U/L). 
LOB activities for striatal and mesencephalic astrocytes increased by 6 (28.4 + 4.6 
U/L) and 160 fold (36.2 + 0.23 U/L) respectively when compared with control values 
(4.59 + 1.83 UIL for striatal and 0.23 + 0.23 UIL for mesencephalic astrocytes). By 
72 h incubation, there is a drastic loss of cell viability with LDH activities reaching a 
106 fold (118.1 + 13.2 U/L) increase in the cortical astrocytes, 24 fold (110.8 + 8.4 
UIL) increase in the striatal astrocytes and 383 fold (87.0 ± 15.3 UIL) increase in the 
mesencephalic astrocytes when compared with control values at 0 h. (Fig.11) 
Based on the marked loss in cell viability after 48 h MPTP treatment, 
astrocytes were not examined for NO production beyond 24 h MPTP treatment. This 
in order that NO produced were not masked by loss of cell viability due to energy 
failure. 
3.2. The effects of MPTP on nitrite levels 
3.2.1 Mesencephalic astrocytes (Fig. 12a) 
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Fig. 11: LDH actIvItIes after 500 ~ :rv.tPTP treatment. Results were ,".~ 
measured from the media released from cortical, striatal & 
mesencephalic astrocytes during 0 - 72 hrs. and expressed as U/L± 
S.E.M. (n=5) 
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It can be observed that there was an increase in extracellular nitrite level in the 
control group that was not treated with MPTP. The nitrite level increased from 0.83 + 
0.06 ~M at 0 h to 4.17 + 0.54 ~M by 24 h. After 500flM MPTP treatment, the 
mesencephalic astrocytes showed a rapid elevation of the nitrite level by 8 h (3.83 ± 
0.37 ~M) incubation. The increase continued to 24 hours of incubation reaching a 56% 
(7.45 + 0.42 ~M) increase of nitrite concentration when compared with the control at 
24 h (4.17 + 0.54 flM). 
3.2.2 Striatal Astrocytes (Fig 12b) 
The control striatal astrocytes showed only a slight increase in nitrite level. 
However, the level of increase was not as high (0.83 ± 0.06 flM at 0 h to 1.56 + 0.19 
flM at 24 h ) when compared to mesencephalic astrocytes. In the MPTP-treated cells, 
a 4 fold increase to 3.71 ± 0.05 ~M was observed at 24 h only with minimal increase in 
nitrate levels observed at earlier time points. 
3.2.3 Cortical astrocytes (Fig 12c) 
There was no significant increase in nitrite level in the control non-treated cells 
with a nitrite range of 0.34 ± 0.04 to 0.83 + 0.06 ~M during the 24 h incubation. The 
increase in nitrite level was also minimal in these astrocytes after MPTP treatment. 
Nitrite level rose from only 0.92 ± 0.05 flM at 0 h to 1.96 + 0.04 flM at 24 h of 
treatment. 
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Fig. 12: Amount of nitrite released into the media from a) mesencephalic 
b) striatal and c) cortical astrocytes from control group and 
. 500JlM :MPTP-treated groups. Pound (#) and stars (*) signs 
indicate significant differences (p<O.05), compared with control 
of the same group and corresponding time point, respectively. 
Mean + SE values of three independent experiments are shown 
** p<O.005; ***p<O.0005 
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3.3. The effects of L-NAME on nitrite levels after MPTP treatment 
Figure 13 showed that L-NAME was capable of blocking the MPTP-induced 
nitrite production from all of the three types of astrocytes. 
Mesencephalic astrocytes when co-incubated with 500~M MPTP and 100~M 
L-NAME, resulted in a reduction of nitrite formation. The level of the nitrite was in 
the range of 0.13 + 0.19 to 1.04 + 0.13 ~M from 0 to 24 h incubation after L-NAME 
treatment. 
L-NAME and MPTP treatment also resulted in the reduction of nitrite 
production in striatal astrocytes (0.06 + 0.05 to 1.04 + 0.13 ~M) as well as cortical 
aStrocytes (0.21 to 0.54 ~M) during 0 to 24 h incubation 
3.4. The effects of Dexamethasone on nitrite levels after MPTP 
treatment 
l~M Dexamethasone had a similar action to that observed for the incubation 
with 100 ~M L-NAME with a reduction of nitrite level observed in all three types of 
astrocytes (Fig 14). 
Nitrite generated by MPTP-treated mesencephalic astrocytes was inhibited by 
l~M dexamethasone with a range of 0.25 + 0.19 to 0.87 ± 0.04 ~M nitrite level from 
o - 24 h incubation. In fact the nitrite production after dexamethasone treatment is 1 to 
16 fold lower than that measured in the control cells from 0 - 24 h (see Fig. 12a). 
In striatal astrocytes, the range of nitrite level ranged from 0 to 1.39 ~M . 
Unlike that of mesencephalic astrocytes the nitrite concentration at 24 h (1.39 + 0.69 
~M) is close to that of the control group (1.56 ± 0.19 ~M) (see Fig 12b). 
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Fig. 13: Amount of nitrite released into the medium from a) mesencephalic 
b) striatal and c) cortical astrocytes in MPTP-treated and 100 JlM 
L-NAME plus MPTP-treated groups. Pound (#) and stars (*) 
signs indicate significant differences (p<O.05), compared with 
control of the same group and corresponding time point, 
respectively. Mean + SE values of three independent experiments 
are shown 
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Fig. 14: Amount of nltnte released into the medium from a) 
mesencephalic b) striatal and c) cortical astrocytes in MPTP-
treated and 1JlM Dexamethasone plus MPTP-treated groups. 
Pound (#) and stars (*) signs indicate significant differences 
(p<O.05), compared with control of the same group and 
corresponding time point, respectively. Mean + SE values of 
three independent experiments are shown 
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Similarly, cortical astrocytes showed a reduction in nitrite formation after 
dexamethasone treatment (ranging from 0 to 0.73 J,1M), reducing nitrite levels to 
control values. 
3.5. Change in intracellular cyclic GMP in astrocytes after MPTP 
treatment 
Figure 15 showed that striatal astrocytes had a higher basal cGMP level (64.5 
finol/dish) when compared with cortical (36.2 finol/dish) and mesencephalic (36.2 
fmol/dish) astrocytes. 
With 500J,1M MPTP treatment, mesencephalic astrocytes showed a rapid rise 
in cGMP level from 4 to 8 h of incubation reaching 151.49 finol/dish by 8 h incubation. 
That is approximately a 3 fold increase when compared with the control group. This 
high cGMP level was maintained between 8 to 12 h incubation and declined to about 
the control level (28.05 fmol/dish) at 24 h of incubation. 
Although striatal astrocytes have a higher basal cGMP level, the elevation of 
intracellular cGMP after MPTP treatment was not as marked as that of mesencephalic 
astrocytes. At 8 h incubation, only an 85% increase in cGMP level was observed, this 
was followed by a return to the control levels by 12 h incubation (66.28 finol/dish) and 
maintained at this level (72.13 fmol/dish) till 24 h incubation. 
There was however minimal change in intracellular cGMP level in cortical 
astrocytes after MPTP treatment with a range of 26.71 to 39.85 finol/dish during the 
treatment period. 
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Fig.15: Change in intracellular cGMP levels of cortical, striatal and 
mesencephalic astrocytes after 500 ~ MPTP treatment. Cells 
. were incubated in fresh EBSS buffer containing 0.6 mM ffiMX, 
20 Vlml SOD and 100 J.1M L-arginine in 37°C for 20 min prior to 
cGMP measurement. cGMP levels were measured at 0, 4, 8, 12, 
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3.6. The effects of MPTP on NFkB distribution in astrocytes 
Since NFlCB is one of the nuclear factors that can induce transcription of iNOS 
mRNA, its nuclear accumulation was used to reflect the iNOS gene expression. LPS 
was shown to be one of the inducers of iNOS. So astrocytes were treated for 6 hours 
in the LPS containing medium and used as a positive control (Fig 16). From the result 
of immunocytochemical staining, it was clear that LPS caused nuclear uptake of p65 
subunit in all the three different types of astrocytes. 
By 8 h of 500~M MPTP incubation, darkly stained nuclei were observed in the 
mesencephalic astrocytes and these positive-stained nuclei were still present at 24 h 
incubation (Fig 17). There are no longer positive-stained nuclei by 48 h post-treatment. 
In striatal astrocytes, numerous darkly stained p65-positive nuclei were 
observed after 4 h MPTP treatment (Fig 18). However, only few stained nuclei can be 
observed at 8 h treatment and from 24 h onwards, no more darkly stained nuclei were 
observed. 
In cortical astrocytes, darkly stained nuclei were observed at the 8 hand 24 h 
post-treatment (Fig 19). By 48 h MPTP treatment, no p65 positive-nuclei could be 
observed. 
3.7. The effects of MPTP on SOD activity in astrocytes 
3.7.1. Mesencephalic astrocytes 
SOD ' activity of control cells was 3.47 + 0.06 U/mg protein (Fig 20). After 
MPTP treatment, a gradual decrease reaching 50% of the control value (1.74 + 0.84 
U/mg protein) by 24 h was observed. The rate of enzyme activity loss was about 0.10 
U /mg protein/h. 
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Fig.16: Immunocytochemical stainIng for p65 subunit of NFKB in -· 
astrocytes cultured in poly-L-Iysine coated 4-well chamber slides. 
Cells were treated with LPS (+LPS) in DMlF12 medium for 6 h 
as positive control. Cells with darkly stained nuclei were treated 
as . positive-stained cells signifying NFkB activation and 
subsequent iNOS induction. Negative control (-1 0 Ab) means 
immunostaining was performed without primary antibody 
addition. (400X magnification) 
1° Ab +LPS 
Fig.I7: Immunocytochemical staining for p65 subunit of NFlCB in ~ 
mesencephalic astrocytes. Darkly stained nucleus were observed 
at 8 hand 24 h after 500 J.1M MPTP treatment. Nuclear staining 
was absent by 48 h treatment. (400X magnification) 
Mesencephalic Astrocytes 
Fig.I8: Immunocytochemical staining for p65 sub unit of NFKB in striatal ~ 
astrocytes. Darkly stained nuclei were observed at 4 h of 500 flM 
. :MPTP treatment and few positive stained cells were detectable at 
8 h treatment. By 24h treatment cells, no positive-stained nuclei 
can be observed. (400X magnification) 
Striatal Astrocytes 
Fig.19: Immunocytochemical staining for p65 subunit of NFKB in cortical t'\:-
astrocytes. Unexpected darkly stained nuclei were observed at 8h -
and 24 h MPTP treatment. No positive stained cells were detectable 
by 48 h post-treatment. (400X magnification) 
Cortical Astrocytes 
Fig.20: Change in total SOD activity in mesencephalic, striatal and cortical 
astrocytes after 500 ~M MPTP treatment. Stars (*) signs indicate 
. significant differences (p<0.05), compared with control of the 
same group and corresponding time point, respectively. Mean + 
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3.7.2. Striatal astrocytes 
The basal SOD activity in striatal astrocytes was 3.50 + 0.55 U/mg protein 
which is similar to that of mesencephalic astrocytes. However, by 8 h of MPTP 
treatment, there was a significant increase of 55% (p< 0.05) in SOD activity (5.42 + 
0.60 U/mg protein). By 24 h incubation, SOD activity returned to near control level of 
3.15 ± 0.27 U/mg protein (Fig 20). 
3.7.3. Cortical astrocytes 
Cortical astrocytes showed a higher basal SOD activity when compared to 
mesencephalic and striatal astrocytes with a SOD activity of 4.30 ± 0.13 U/mg protein. 
After 500pM MPTP treatment, a gradual decrease was observed from 0 - 24 h 
reaching a 26% decrease in SOD activity at 24 h (3.16 ± 0.51 U/mg protein). The 
decline rate of SOD activity measured was about 0.05 U/mg protein!h. 
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CHAPTER 4 DISCUSSION AND CONCLUSION 
The present study showed that cGMP, nitrite and nitrate levels were elevated in 
the astrocytes after 24 h MPTP treatment. This is the first study to report that 
astrocytic NO was produced in response to MPTP treatment. The source of the NO 
was later confirmed to be due to the activation of NOS with the use of NOS inhibitor 
L-NAME (see Section 2.5). L-NAME is one of the L-arginine analogs and is highly 
soluble in water therefore it is commonly used as a general NOS inhibitor. L-NAME 
(100~M) was first added to the MPTP containing-medium and incubated with the 
astrocytes for different intervals. From as early as 4 h incubation, L-NAME almost 
completely blocked MPTP-induced nitrite formation in astrocytes from all 3 regions. 
This indicated that the nitrite measured was due to the metabolism of NO and not 
other cellular sources. To further identify which of the 3 isoforms of NOS was 
involved in the catalysis of NO, l~M dexamethasone was also incubated with MPTP 
during the different time intervals tested. Dexamethasone is a glucocorticoid which 
was shown to be effective in the · suppression of NFlCB-activated iNaS expression. 
Other than this, dexamethasone can also de stabilize the iNaS protein. The result of 
dexamethasone was similar to that of the L-NAME where the production of nitrate 
was almost completely blocked. Therefore, iNaS was likely to be the candidate 
responsible for induction of NO formation observed after MPTP treatment. Further 
confirmation of NFlCB-induced iNaS transcription was obtained in the 
immunocytochemical study where NFlCB p65 subunit positive-stained nuclei were 
observed during the 24 h MPTP treatment. This further showed that iNOS was indeed 
involved in the process of NO production in astrocytes after MPTP treatment. 
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In the present study, astrocytes from different brain regions seemed to respond 
differently to the MPTP treatment. Mesencephalic astrocytes seemed to be more 
sensitive to oxidative stress since control cells showed an increase in nitrite formation 
during the 24 h incubation period (Fig 12a). These results were similar to those 
obtained in earlier studies in our laboratory where only mesencephalic astrocytes, 
without MPTP treatment, were shown to generate ROS as early as 2 h of incubation 
(Wong et al., 1997). In the present study, MPTP treatment seemed to generate the 
highest amount of nitrite in mesencephalic astrocytes by 24 h incubation when 
compared to striatal and cortical astrocytes (Fig. 12). These cells also showed the 
largest increase in intracellular cGMP content, reaching a peak: value of 165 fmo1/dish 
by between 8 - 12 h (Fig 15). These changes in cGMP level may reflect the changes in 
intracellular NO concentration at that particular time point studied. However, the 
decline in cGMP from 12 h may be due to a negative feedback of NO as well as the 
extrusion of these molecules out of the cells (Griscavage et al., 1993; Park et al., 1994; 
Murphyet al., 1995; Matthews et al., 1996). Although striatal astrocytes also showed 
a similar rise of nitrite and cGMP levels, the peak: levels were lower than (50.2% less 
in nitrite at 24 h; 72.5% less in cGMP peak: level) that of mesencephalic astrocytes. 
Cortical astrocytes, however, showed minimal change in the nitrite and cGMP 
activities after 24 h treatment. These results implied that mesencephalic astrocytes are 
more susceptible to the induction of NO production by MPTP when compared with 
astrocytes from the other two regions. 
ROS may be one of the possible mediators for NO formation observed in the 
present study. Several studies had suggested the possible linkage between ROS and 
NO production (Malinski et al., 1993; Morita et al., 1994) with H20 2 being shown to 
induce iNOS expression in a variety of epithelial cells (Adcock et al., 1994; Milligan et 
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al., 1996; Peresleni et al., 1996). Although the mechanisms mediating iNOS induction 
after exposure to ROS remained unknown, it is possible that oxidant-sensitive 
transcription factors like NFlCB may be involved and are upregulated during 
oxidative-induced injuries (Schreck et al., 1992; Meyer et al., 1993; Adcock et al., 
1994). 
In the present study, an increase in NFlCB expression with MPTP treatment 
suggested that this may be due to an induction of the iNOS gene. Furthermore, the 
time course of NFlCB accumulation into the nuclei was similar to the pattern of cGMP 
production in striatal and mesencephalic astrocytes but not in cortical astrocytes. Peak 
nuclear accumulation of NFlCB was observed in striatal astrocytes 4 h after MPTP 
treatment (Fig. 18) whereas mesencephalic and cortical astrocytes showed 
NFlCB-positive nuclei only from 8 h post-treatment (Figs 17 & 19 respectively). 
Striatal astrocytes seemed to response to MPTP insult earlier than cortical and 
mesencephalic astrocytes in terms of NFKB activation and cGMP production 
suggesting that they are responsive. to NO production. 
Mesencephalic astrocytes however showed NFKB-positive cells from 8 - 24 h 
MPTP treatment (Fig 17), a much more prolonged activation when compared to 
striatal astrocytes. This is reflected in the cGMP level where striatal astrocytes showed 
a earlier peak than mesencephalic astrocytes. The prolonged nuclear accumulation of 
the NFlCB may partly explain why mesencephalic astrocytes had a higher nitrite and 
cGMP level. 
Unexpectedly, cortical astrocytes, which did not show much change in both 
cGMP and nitrite level, have a high level of nuclear NFKB accumulation. One possible 
explanation may be although there is the trans~ription of iNOS, there is however a lack 
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of translation of iNOS mRNA in cortical astrocytes. Nuclear NFKB accumulation only 
caused iNOS gene transcription (Fig. 5) and not translation, the lack of iNOS protein 
expression in cortical astrocytes may be due to the lack of translation. To test this 
hypothesis, western blotting of the iNOS protein and concomitant northern blotting of 
iNOS mRNA can be used .. 
The results at present confirmed our present and preVIOUS findings that 
mesencephalic and striatal astrocytes are more sensitive to oxidative-induced injuries 
and cortical astrocytes, although also respond to oxidative injuries, are less severely 
affected. 
It had been reported that there may also be a differential susceptibility of the 
different cell types in the eNS to NO (Mitrovic et al., 1994; Bolanos et al., 1995) with 
oligodendrocytes being the most sensitive to NO toxicity, followed by astrocytes and 
microglia showed the highest tolerance. Therefore it is not surprising that there were 
differential responses observed in the present study. It can be speculated that the 
factors responsible for this difference may be due to the difference in intracellular 
antioxidant levels, namely SOD activity and GSH content. SOD can scavenge Oi-, 
therefore high SOD activity can minimize the chance of ONOO- formation. GSH can 
act as an important intracellular defense against ONOO- because ONOO- can also 
decompose to form the powerful and cytotoxic OH- and to nitrogen dioxide (N02) 
spontaneously, which are potent activators of lipid peroxidation (Beckman et al., 1990; 
Radi et al, 1991b; Crow, et al., 1994) (Fig 7). High GSH level can therefore help to 
prevent the formation of OH- resulting from ONOO- decomposition (Barker et al., 
1996). 
The present study also showed a regional difference in SOD activities in the 
astrocytes from the different regions. Striatal and mesencephalic astrocytes were 
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shown to have lower basal · SOD levels when compared with cortical astrocytes. 
Mesencephalic astrocytes again showed the most rapid decrease in SOD activities, 
reaching a 50% decrease by 24 h treatment. This decline may be partially due to the 
low GSH content found in these cells (unpublished data). Koningsberger et al. (1994) 
had demonstrated that H20 2 could reduce SOD-bound Cu2+ to Cu+ thus inactivating it. 
So> it is possible that if the production of H20 2 was too fast in these astrocytes and 
exceed the capacity of the GSH system, H20 2 would accumulate rapidly and inactivate 
SOD. Reduced activity of SOD would reduce its capacity to catalyze O2'- production. 
The accumulation of O2'- will lead to the formation of H20 2• If the rate of H20 2 
production exceeds the rate of their removal, free H20 2 would reacted with Fe2+ ions to 
form hydroxyl free radical (OH") by the Fenton reaction (Fig. 4). OH' can be highly 
reactive and could react with most of the cell components, resulting in cell death from 
lipid peroxidation. Coupled with lower endogenous level of GSH, thus the low 
efficiency in removing H20 2, mesencephalic astrocytes may as a result, be less 
protective to the dopaminergic neuronal cells. Cell bodies of the dopaminergic 
neurons, located at the SN were normally under less oxidative stress when compared 
to that of their dopaminergic terminals. Therefore, mesencephalic astrocytes may be 
less adaptive to high levels of free radicals generated. 
Our present finding showing differential changes in SOD activities in astrocytes 
was supported by the work of Thiffault and his colleagues (1995). They showed a one-
to three fold increase in Mn-SOD and CuZn-SOD activities in the striatum of C57BL/6 
mice 2 h after MPTP injection (3 x 20 mg/kg at 2 h interval). This is followed by a 
decrease. A 50% decrease in Mn-SOD was noted in SN of these mice. Their results 
are very similar to the present in vitro study where a transient increase in SOD activity 
in striatal astrocytes and a 50% decrease in SOD activity at 24 h treatment in 
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mesencephalic astrocytes were observed. Several lines of evidence have 
demonstrated that SOD is upregulated when cells are exposed to excessive production 
of 02"-. (Sjostrom and Crapo, 1981; Stevens and Autor, 1977) suggesting that the 
current elevation of SOD activity in striatal astrocytes may reflect an increase 
formation of 02"- during MPTP treatment. 
In earlier studies from our laboratory, it was also shown that mesencephalic 
astrocytes had the lowest endogenous GSH level (55.69 ± 3.73 nmole/mg protein) 
whilst cortical (76.93 ± 5.41 nmole/mg protein) and striatal (79.28 ± 6.36 nmole/mg 
protein) astrocytes had higher concentrations (unpublished data). This indicated that 
mesencephalic astrocytes are less capable in removing H20 2 and therefore are more 
susceptible to oxidative stress. It was also shown from this study that GSH levels 
depleted most rapidly in mesencephalic astrocytes (from 12 h incubation of 500 pM 
MPTP), with a 43% decrease in GSH level at 24 h. The depletion of MPTP is less 
severe in cortical astrocytes (17% decrease at 24 h) and striatal astrocytes (16% 
decrease at 24 h) (unpublished data). Therefore, it can be speculated that GSH in this 
circumstance, may be a contributory factor to the increased susceptibility of NO 
production observed in the mesencephalic astrocytes. 
Furthennore, since GSH. had been shown to be an important factor in 
protecting the cells against peroxynitrite (ONOO-), astrocytes that are depleted of 
GSH, when exposed to ONOO-, may result in mitochondrial damage and cell death 
(Barker et al., 1996). Another study showed that in depleting GSH, MPTP- and 
MPP+ -induced toxicity to nigral dopaminergic neurons were potentiated (Wullner et 
al., 1996). These results strongly suggested that the cellular GSH status may play an 
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important role in NO-mediated neurotoxicity (Barker et ai, 1996; Bolanos et al., 
1996). 
Striatal astrocytes on the other hand showed a transient elevation of SOD 
activity at 8 h incubation with 500 pM MPTP. The increase in SOD activity suggested 
that the striatal astrocytes may possess some protection towards the increased 02"-
generated during MPTP treatment. This suggested that the . striatal astrocytes may be 
more adaptive to oxidative stress since there is a high turnover rate of DA at the 
neuronal terminal and therefore large amounts of 02"- and H20 2 will be generated. The 
increased SOD activity in striatal astrocytes may help to scavenge the 02"- formed, 
thus reducing the amount of 02"- that would react with NO to fonn ONOO-. This may 
render striatal astrocytes themselves and/or their neighbouring neurons more resistant 
to the NO toxicity. 
How NO was produced and how the activation of iNOS in astrocytes can 
mediate neuronal degeneration in PD is still a matter of debate although previous 
studies plus the current findings showed that astrocytes may play a role in 
NO-mediated neurotoxicity after MPTP treatment. 
Dawson et al. (1994) and Chao et al. (1996) demonstrated that increased 
expression of iNOS in mixed astrocytic-neuronal cocultures caused neuronal cell death 
after exposure. Bolanos et al. (1996) sh-owed that coincubation of iNOS-expressing 
astrocytes with neurons caused a NO-dependent neuronal loss of ATP, indicating that 
neuronal loss of A TP and neuronal energy depletion may be a mechanism for 
astrocytic-derived NO-mediated neuronal toxicity. Although the above evidence 
suggested that increase expression of iNOS may be neurotoxic, the mechanism 
whereby this neurotoxicity occurs still awaits further experimentation. To further test 
49 
this, a coculture system of DA neurons with astrocytes over-expressed with the iNOS 
gene may provide more clues to the role of iNOS in MPTP-induced toxicity. Under 
this coculture condition, the investigation into the mode of neuronal cell death, for e.g. 
through DNA damage, lipid peroxidation or energy depletion, will further elicit the 
mechanisms involved. 
Although the induction of iNOS in glial cells had been shown to be associated 
usually with pathological conditions (Murphy and Guzybicki, 1996) and that current 
evidence of PD postmortem brains showed that there were iNOS positive glial cells in 
the SN (Hunot et al., 1996), a direct relationship between increased NO synthesis 
arising from iNOS induction, and the subsequent DA neuronal cell death still needs to 
be established. 
In conclusion, the present study showed that astrocytes from different regions 
of the brain showed differential levels of basal antioxidant level and variable responses 
to MPTP-induced NO formation. Striatal astrocytes, which are associated with DA 
axonal terminals, seemed to provide more protection to the neurons against 
oxidative-induced injury. On the other hand, mesencephalic astrocytes, associated with 
DA neuron cell bodies, were shown to be more susceptible to MPTP-induced 
oxidative stress, by having lower antioxidant levels as well as producing higher 
quantities of NO. Therefore these cells seemed less adaptive in providing protection to 
nearby DA neuronal cell bodies against oxidative stress. 
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